Japan’s Chugai Forecasts Record-Setting Profit Decline In 2008
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical of Japan, a Roche Holding subsidiary, expects its profits this year to decline more than in any year in its 24-year history, the company reported. The company cited lower drug prices ordered by the government and drops in sales of its three best-selling drugs. Chugai also voluntarily lowered the price of its best-selling Epogin last July in an effort to compete with Kirin Holdings' competing product. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.